Risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990-1992
Permanent link
https://hdl.handle.net/10037/26619Date
2020-08-30Type
Master thesisMastergradsoppgave
Author
Riibe, Marit ØstlyngenAbstract
Background/objective: Long-term follow-up of patients with positive tests for Human Papilloma Viruses (HPV) is rarely studied. The study objective was to compare HPV status at baseline with the outcome of CIN3+ in the follow-up period of 28 years.
Materials and methods: All women referred to the HPV outpatient clinic at the University Hospital of Northern Norway (UNN) in 1990-1992, having a HPV test performed during that time, were included in this retrospective cohort. An exposed cohort with positive high-risk (HR) HPV test was compared to a control cohort with negative HR-HPV test. Both cohorts were followed up to the last time-point of observation of 28 years.
Results: The risk of CIN2+ among HPV positive and HPV negative women was 57.0% (127/223) and 17.4% (73/419), respectively (p<0.01). Among the 223 HR-HPV positive women, 102 (45.7%) developed CIN3+, while 44 (10.5%) out of 419 HPV negative women developed CIN3+ (p<0.01). The overall cumulative incidence of CIN3+ was 22.7%. Women with HPV33 had the highest incidence of CIN3+, but HPV16 provided the greatest long-term risk of CIN3+. The incidence of CIN3+ was similar for women with a negative HR-HPV test and women with a positive low-risk (LR) HPV test, including HPV 6 and 11.
Conclusion and consequences: HPV status at baseline is predictive for women ́s subsequent risk of developing CIN3+. Women with a positive HR-HPV test in 1990-1992 had a significantly higher risk of CIN3+ during 28 years of follow-up compared to HR-HPV negative women. The cumulative incidence of CIN3+ within the two groups were quite similar to that of CIN2+, suggesting that most women with prevalent CIN2+ also developed CIN3+. Our results suggests that detection of LR-HPV types does not predict CIN3+ and therefore should be omitted from primary screening for cervical cancer.
Publisher
UiT Norges arktiske universitetUiT The Arctic University of Norway
Metadata
Show full item recordCollections
Copyright 2020 The Author(s)
The following license file are associated with this item: